Third Year Evaluation on Genistein Efficacy and Safety
Third Year Evaluation on Genistein Efficacy and Safety
BACKGROUND: Recent evidences showed that the phytoestrogen genistein positively affects bone
 metabolism with no clinically significant adverse effects in a cohort of osteopenic,
 postmenopausal women. However, there is still a knowledge gap regarding the long-term safety
 of genistein on the breast, the uterus, the thyroid gland and its efficacy in postmenopausal
 women.

 OBJECTIVE: To assess the safety profile of genistein on mammary and thyroid glands and
 endometrium and cardiovascular apparatus and its effects on bone metabolism after a 3-year
 therapy with pure, standardized genistein (54 mg/day).
DESIGN: The parent study was a randomized, double-blind, placebo-controlled trial involving
 389 osteopenic, postmenopausal women for 24 months. After the 24-month visit, a
 sub-population (138 patients) accepted to continue the intervention until 36 months, thus
 generating a follow-up study.

 SETTING: 3 Italian university medical centers. INTERVENTIONS: Participants received 54 mg of
 genistein, daily, (n=71) or placebo (n=67). Both intervention and placebo contained calcium
 and vitamin D3. All patients also received dietary instruction in an isocaloric fat-reduced
 diet.

 MEASUREMENTS: Mammographic breast density at baseline and after 24 and 36 months was assessed
 by visual classification scale and by digitized quantification. BRCA1 and BRCA2 molecular
 message, sister chromatid exchanges and endometrial thickness were also evaluated at the same
 time points. Measurements of lumbar spine and femoral neck BMD and QUS t-score were assayed
 in our patients. Secondary outcomes were serum levels of B-ALP, IGF-I, sRANKL,
 osteoprotegerin and urinary excretion of CTX, pyridinoline and deoxypyridinoline. Furthermore
 insulin resistance (HOMA-IR), glucose levels, homocysteine and hot flushes were also
 evaluated. In addition for thyroid safety TSH, fT3, fT4, thyroid autoantibodies, and mRNA for
 thyroid and retinoid receptors were evaluated.
Inclusion Criteria:

 -  Good general health

 -  Have not had a menstrual period in the preceding year

 -  Had not undergone surgically induced menopause

 -  Had a follicle-stimulating hormone level > 50 IU/liter and a serum 17 beta-estradiol
 level ≤ 100 pmol/liter

 -  Established osteopenia (-1<T-score<-2.5 SD)

 Exclusion Criteria:

 -  Clinical or laboratory evidence of confounding systemic diseases, such as
 cardiovascular, hepatic, or renal disorders

 -  Coagulopathy, use of oral or transdermal estrogen, progestin, androgen or other
 steroids

 -  Biphosphonates, cholesterol-lowering therapy or cardiovascular medications in the
 preceding six months

 -  Smoking habit of more than two cigarettes per day

 -  Previous treatment with any drug that could affect the skeleton in the preceding year

 -  A family history of estrogen-dependent cancer

 -  BMD at femoral neck > 0.795 g/cm2; this BMD value corresponds to a T score of -1
 standard deviation